One example of this is the FAPα-activated prodrug Z-GP-DAVLBH, that selectively destroys pericyte-rich vessels, eradicating the otherwise VDAs-resistant tumor rim and leading to complete tumor regression in pre-clinical models [110]. The gene discussed is FAP; the disease is neoplasm.